Key result
Sacubitril/valsartan was superior to ARB therapy in reducing the composite of cardiovascular death and hospitalization for worsening HF.
Why the study?
The study aimed to compare the efficacy of ARNI therapy with ARB therapy for cardiovascular outcomes in real-world patients with heart failure with reduced ejection fraction.
Does sacubitril/valsartan reduce the composite of cardiovascular death and hospitalization for worsening heart failure compared to ARB therapy in patients with HFrEF?
Cohort
Does sacubitril/valsartan reduce the composite of cardiovascular death and hospitalization for worsening heart failure compared to ARB therapy in patients with HFrEF?
Answers are grounded in this paper and cite their sources.
In a real-world Taiwanese cohort of HFrEF patients, sacubitril/valsartan significantly reduced the composite of cardiovascular death and heart failure hospitalization compared to ARB therapy, despite the use of lower-than-trial doses.
AIMS: This study aimed to compare the efficacy of angiotensin receptor-neprilysin inhibitor (ARNI) therapy with angiotensin receptor blocker (ARB) therapy for cardiovascular outcomes in patients with heart failure (HF) with reduced ejection fraction. METHODS AND RESULTS: Data were obtained from the Chang Gung Research Database. The cohort entry date of the ARB group was assigned as that of the ARNI group to avoid immortal time bias. Additionally, 1:1 propensity score matching based on age, sex, and baseline left ventricular ejection fraction was conducted. The expectation-maximization imputation method with inverse probability of treatment weighting was used to compare outcomes between the two groups. The primary outcome was a composite of cardiovascular death and hospitalization for worsening HF. Patients who received ARNI therapy had a significantly lower risk of the primary composite outcome occurring than patients who received ARBs (hazard ratio, 0.74; 95% confidence interval, 0.57-0.96). The reduction of hospitalization for worsening HF contributed most to the primary outcome benefits. In addition to the primary outcome, the ARNI group had a significantly lower risk of non-fatal myocardial infarction. The improvement of ejection fraction was not significantly different between the groups. The medication doses of ARNI were lower than in clinical trials. CONCLUSIONS: In patients with HF with reduced ejection fraction, sacubitril/valsartan was superior to ARB therapy in reducing the occurrence of the primary outcome endpoint of hospitalization for worsening HF and cardiovascular death.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2020) conducted a cohort in Heart failure with reduced ejection fraction. Sacubitril/valsartan vs. Angiotensin receptor blocker (ARB) therapy was evaluated on Composite of cardiovascular death and hospitalization for worsening HF (HR 0.74, 95% CI 0.57-0.96). Sacubitril/valsartan was superior to ARB therapy in reducing the composite of cardiovascular death and hospitalization for worsening HF.
Synapse has enriched 10 related papers. Consider them for comparative context: